Currently recruiting for the following tumor types:

**DOGS** - Transitional cell carcinoma (bladder), lymphoma

**CATS** – No enrolling trials at this time.

1. **TUMOR TYPE: Canine Bladder transitional cell carcinoma**

**TRIAL:** Evaluating a novel optical imaging agent, fluorocoxib A, to detect cyclooxygenase-2 (COX-2) expressing cancers of bladder in female dogs.

COX-2 enzyme is highly present in cancer cells, but not in normal cells that makes an attractive target for detection of cancer. This study using fluorocoxib A in dogs with naturally occurring cancers will assist to identify tumors that would benefit from COX-2 targeted NSAIDs. In addition, this study will assist to translate this novel imaging agent into clinical applications for detection of cancer, as well for monitoring the early responses to therapy not only in dogs, but also in human patients. This trial includes financial incentives to the client. Patients may be enrolled undiagnosed and the trial will pay for biopsy for diagnosis. Patients must be off NSAIDs for 2 weeks before enrollment or biopsy. Female dogs only. Trial period is approximately 24 hours.

*PI- Dr. Maria Cekanova, mcekanov@utk.edu*

2. **TUMOR TYPE: Canine Lymphoma**

**Trial:** Effect of high omega-3 and low carbohydrate diet on lymphoma remission and survival in dogs

**Patient Eligibility:** Dogs diagnosed with all stages of *naive* lymphoma planning to undergo a standard of care chemotherapy protocol (Madison Wisconsin Protocol) will be eligible. They will be randomly assigned to one of three diet treatment groups. Patients will be excluded if they have other systemic disease that is expected to shorten their lifespan or would preclude feeding the experimental diet. Examples include chronic kidney disease or proteinuria, history of pancreatitis, hypertriglyceridemia, or inflammatory bowel disease. Patients must be treated at UT. **Financial Compensation:** In exchange for participating in this study, your pet will receive a natural premium dog food for up to 2 years free of cost.

*PIs: Angela Witzel, DVM, PhD, DACVN witzel@utk.edu, Olya Martin, DVM, DACVIM (oncology) Opuretsk@utk.edu*

**PLEASE NOTE:**

For all trials, patients must be examined at UTCVM to determine eligibility. **If a patient is being seen specifically for clinical trial evaluation, please contact the Clinical Trials Coordinator to schedule an appointment (no Referral form required).** If a patient is referred to Oncology and you would like a clinical trial to be considered, please make a note on the referral form.

Clients may be responsible for the initial examination fee for the screening visit (currently $132). While additional tests may be required, each trial has different funding; therefore, an explanation of costs will be reviewed with the client.